Nilandron

Active Ingredient(s): Nilutamide
FDA Approved: * September 19, 1996
Pharm Company: * SANOFI AVENTIS US
Category: Cancer

Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer.[7][8][9][10][11][12] It has also been studied as a component of feminizing hormone therapy for transgender women and to treat acne and seborrhea in women.[13][14][15][16] It is taken by... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Nilandron 168D
Nilandron 150 mg Oral Tablet
NDC: 0088-1111
Labeler:
Sanofi-aventis U.S. LLC
Nilandron 168D
Nilandron 150 mg Oral Tablet
NDC: 24987-111
Labeler:
Covis Pharmaceuticals, Inc.
Nilandron 168D
Nilandron 150 mg Oral Tablet
NDC: 59212-111
Labeler:
Concordia Pharmaceuticals Inc.